David W Hillman

8PUBLICATIONS
80CO-AUTHORS
Haematological tumoursPredictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 17, 2024
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).

Jeffrey L Jensen, Olivia Bobek, Irenaeus C C Chan

|Mar 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer.

Roberto A Leon-Ferre, Jodi M Carter, David Zahrieh

|Jan 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).

Rahul Aggarwal, Glenn Heller, David W Hillman

|Nov 04, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.

Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet

|Apr 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.

Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld

|Mar 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).

Michael J Morris, Glenn Heller, David W Hillman

Pageof 2

Frequent Collaborators

3 joint publications

Michael J Morris

3 joint publications

Alan H Bryce

2 joint publications

Susan Halabi

2 joint publications

Olivia Bobek